-

EmeraNova™ Expands Access to Wound Imaging, Supporting Clinical Diagnostic Capabilities

Kent Imaging Joins EmeraNova’s Toolbox of Tissue Restoration Technologies

PHOENIX--(BUSINESS WIRE)--Following yesterday’s milestone launch announcement, EmeraNova™, the new corporate identity of BioLab Holdings and a medical technology company building an advanced tissue restoration platform, has announced a collaboration that will expand its portfolio into an entirely new category and allow it to enter additional care settings. Technology leader Kent Imaging is teaming up with EmeraNova to bring advanced wound imaging to wound care clinics, surgical centers, hospitals and HOPDs.

“This collaboration with Kent Imaging is a proof point of the direction we’re headed.”

Share

“This collaboration with Kent Imaging is a proof point of the direction we’re headed,” said EmeraNova President & CEO Jaime Leija. “Not only are we expanding the diagnostic category of our toolbox of products, a crucial step in the tissue restoration journey, but these technologies will allow us to aid clinicians’ ability to make diagnoses in a much wider range of care settings, providing a deeper, more advanced look into a patient issue.”

Kent Imaging’s SnapshotNIR and SnapshotGLO work together to reveal two key barriers to repair—low tissue oxygenation and elevated bacterial bioburden. With dual imaging insights, clinicians gain clarity, confidence, and speed in decision-making, supporting earlier, more targeted interventions that optimize treatment and reduce delays.

SnapshotNIR is non-invasive, cost effective, and measures and reports approximate values of tissue oxygen saturation (StO2), relative oxyhemoglobin, relative deoxyhemoglobin in superficial tissue. SnapshotGLO is an adjunctive tool that uses ultraviolet light via a handheld portable device to provide users with a visual of elevated bacterial loads in a wound by detecting fluorescence emitted from bacteria at loads greater than 10⁴ CFU/g*.

“The strongest clinical decisions begin with a clearer understanding of what is happening beneath and around a wound,” said Pierre Lemire, CEO of Kent Imaging. “Partnering with EmeraNova allows us to pair advanced imaging insights with a broader tissue restoration strategy, helping clinicians connect assessment to next steps with greater confidence.”

The collaboration reflects EmeraNova’s continued strategy of building one of the industry's most comprehensive tissue restoration toolboxes through partnerships with companies developing advanced regenerative, imaging and therapeutic technologies. Through its commercialization network, EmeraNova will support broader adoption of Kent Imaging’s technologies across care settings nationwide.

For more information on EmeraNova's toolbox of tissue restoration products, visit emeranova.com.

About EmeraNova™

EmeraNova™ is a leading medical technology company advancing tissue restoration across healing phases, care settings, and specialties by building a global platform that identifies promising technologies from around the world and accelerates their path into clinical practice. Through an expanding toolbox of tissue restoration solutions, world-class support, and a commitment to bringing together expert voices and clinical insights, EmeraNova aims to help shape what’s possible in tissue repair. BLS Labs, LLC and BLS Sales & Marketing, LLC, are accredited by the Association for Advancing Tissue and Biologics (AATB), reflecting the organization’s commitment to rigorous standards for quality, safety and operational excellence. For more information, visit emeranova.com.

About Kent Imaging

Based in Calgary, Alberta, Canada, Kent Imaging is a leading innovator in advanced imaging technology. The company designs, manufactures, and markets medical devices that support real-time decision-making in wound care, vascular, and surgical specialties. Through patented technologies, Kent continues to deliver groundbreaking solutions that support healthcare systems around the world.

The Snapshot product suite now includes two powerful imaging devices: SnapshotNIR, a near-infrared tissue oxygenation imaging device initially cleared by the FDA and Health Canada in 2017 and CE-marked in 2025; and SnapshotGLO, a bacterial autofluorescence imaging device that received FDA 510(k) clearance in 2025. SnapshotNIR is supported by clinical evidence demonstrating its role in enhancing clinical decision-making, while SnapshotGLO provides real-time insight into wound bioburden presence and distribution. Together, the Snapshot product family strengthens clinicians' ability to detect, direct, and protect—promoting treatment consistency, supporting improved workflow, and contributing to better patient care worldwide.

SnapshotGLO® is a registered trademark of Kent Imaging Inc.

SnapshotNIR® is a registered trademark of Kent Imaging Inc.

Contacts

Contact: Kwyn Lowe
Phone: 406.314.5120
Email: klowe@emeranova.com

EmeraNova


Release Versions

Contacts

Contact: Kwyn Lowe
Phone: 406.314.5120
Email: klowe@emeranova.com

More News From EmeraNova

EmeraNova™ Continues to Lead in Innovation By Launching Accelerator Program

PHOENIX--(BUSINESS WIRE)--EmeraNova™, a Phoenix-based medical technology company specializing in advanced tissue restoration technologies, is amplifying its mission to seek out new innovations and bring them to market through the launch of Catalyst. Catalyst, an EmeraNova™ Accelerator, is a four-month accelerator designed for startups at the frontier of tissue restoration and advanced wound care, which will include validation, mentorship, and investment opportunities. Applications are open now.C...

EmeraNova™ Adds Hyaluronic Acid Matrix Technology, Supporting Expansion to New Care Settings

PHOENIX--(BUSINESS WIRE)--EmeraNovaTM, the new corporate identity of BioLab Holdings and a medical technology company building an advanced tissue restoration platform, is expanding its tissue preparation and restorative capabilities through a new commercialization collaboration with Hyalomatrix®.Hyalomatrix is a regenerative matrix built on hyaluronic acid technology to support tissue regeneration and complex wound healing. The technology joins EmeraNova’s growing toolbox of solutions designed t...

BioLab Holdings Launches EmeraNova™ to Advance the Future of Tissue Restoration

PHOENIX--(BUSINESS WIRE)--BioLab Holdings announced today a new, larger mission with the launch of EmeraNova™, a new corporate identity that reflects a broader ambition to advance tissue restoration across specialties, healing phases, and care settings. The launch marks the company’s efforts to build a global platform focused on identifying promising technologies and accelerating their path into clinical practice. EmeraNova represents a vision to pursue emerging (Emer) and new (Nova) technologi...
Back to Newsroom